Circulating Cell-Free DNAs as a Biomarker and Therapeutic Target for Acetaminophen-Induced Liver Injury.
Madi SunPeiyu ChenKai XiaoXiang ZhuZhibin ZhaoChenyang GuoXuan HeTongfei ShiQingguo ZhongYong JiaYu TaoMingqiang LiKam W LeongDan ShaoPublished in: Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023)
Acetaminophen (APAP) overdose is a leading cause of drug-induced liver injury and acute liver failure, while the detection, prognosis prediction, and therapy for APAP-induced liver injury (AILI) remain improved. Here, it is determined that the temporal pattern of circulating cell-free DNA (cfDNA) is strongly associated with damage and inflammation parameters in AILI. CfDNA is comparable to alanine aminotransferase (ALT) in predicting mortality and outperformed ALT when combined with ALT in AILI. The depletion of cfDNA or neutrophils alleviates liver damage, while the addition of cfDNA or adoptive transfer of neutrophils exacerbates the damage. The combination of DNase I and N-acetylcysteine attenuates AILI significantly. This study establishes that cfDNA is a mechanistic biomarker to predict mortality in AILI mice. The combination of scavenging cfDNA and reducing oxidative damage provides a promising treatment for AILI.
Keyphrases
- liver failure
- oxidative stress
- cell free
- hepatitis b virus
- cardiovascular events
- cell therapy
- type diabetes
- bone marrow
- risk factors
- drug induced
- coronary artery disease
- metabolic syndrome
- cardiovascular disease
- adipose tissue
- acute respiratory distress syndrome
- adverse drug
- label free
- combination therapy
- wild type
- high fat diet induced